How do visceral fat and subcutaneous fat loss differ on GLP-1s?

GLP-1 medications reduce both visceral (deep abdominal) and subcutaneous (under skin) fat, but visceral fat loss is particularly beneficial for metabolic health. Visceral fat surrounds organs and produces inflammatory cytokines that drive insulin resistance and cardiovascular disease. GLP-1s appear particularly effective at reducing visceral adipose tissue - studies show significant reductions in waist circumference and hepatic fat content. Subcutaneous fat loss contributes more to visible body changes and clothing size reductions. DEXA scans or bioimpedance analysis can track both types separately. Even modest weight loss (5-10%) produces disproportionate visceral fat reduction and metabolic improvements. The pattern of fat loss varies by individual - some lose more from the midsection first, others from hips and thighs. Both types of fat loss improve health outcomes.